SLG
LOGC

Stanley-Laman Group’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Stanley-Laman Group’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-19,530
Closed -$211K – 299
2019
Q3 		$211K Hold
19,530
– – 0.05% 257
2019
Q2 		$254K Buy
+19,530
New +$259K 0.06% 249

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Stanley-Laman Group's LOGC Position: Q4 2019 in Review

Stanley-Laman Group sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2019, closing a stake of 19,530 shares — an estimated $211K sold.

Stanley-Laman Group first reported a position in LOGC in Q2 2019 and held it in 2 quarters. The position peaked at $254K in Q2 2019. 44 funds tracked by Wall St. Rank hold LOGC as of Q4 2019.

  • Stanley-Laman Group reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Stanley-Laman Group sold 19,530 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $211K.
  • Stanley-Laman Group first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q2 2019 and held it in 2 quarters.
  • Stanley-Laman Group's LogicBio Therapeutics, Inc. Common Stock position peaked at $254K in Q2 2019.
  • 44 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Stanley-Laman Group's 13F filing for Q4 2019, filed 4 Feb 2020.